This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chelsea Therapeutics' CEO Presents FDA Advisory Committee Update - Conference Call (Transcript)

Chelsea Therapeutics International Ltd. ( CHTP)

Special Call

February 23, 2012 5:30 pm ET


Kathryn McNeil – Head-Investor & Media Relations

Simon Pedder – President & Chief Executive Officer

William D. Schwieterman – Chief Medical Officer

William B. White – Chief, Hypertension and Clinical Pharmacology Division & Professor, Department of Medicine, University of Connecticut Health Center


Robyn Karnauskas – Analyst, Deutsche Bank Securities, Inc.

Jonathan M. Eckard – Analyst, Leerink Swann LLC

Liana Moussatos – Analyst, Wedbush Securities, Inc.

Juan F. Sanchez – Analyst, Ladenburg Thalmann Securities

David S. Moskowitz – Analyst, ROTH Capital Partners LLC

Martin Shkreli – General Partner, MSMB Capital Management LLC



Good day, ladies and gentlemen, and welcome to Chelsea Therapeutics’ FDA Advisory Committee Update Conference Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions) As a reminder, this conference call may be being recorded.

I would now like to hand the conference over to Ms. Kate McNeil. Ma’am, you may begin.

Kathryn McNeil

Thank you. Good afternoon, everyone, and thank you for joining us to discuss today’s meeting of the Cardiovascular and Renal Drugs Advisory Committee regarding NORTHERA NDA. Joining me from Chelsea is Dr. Simon Pedder, President and Chief Executive Officer; Dr. Bill Schwieterman, our Chief Medical Officer; Dr. Art Hewitt, our Chief Scientific Officer; and Joe Oliveto, our Chief Operating Officer.

We’re also joined today by Dr. Mark Stacy, Professor of Neurology at Duke Institute for Brain Sciences and Dr. William White, Chief of the Hypertension and Clinical Pharmacology Division at the University of Connecticut Health Center.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs